Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

UNC Lineberger Comprehensive Cancer Center: Clinical Trials & FDA Approval Profile

UNC Lineberger Comprehensive Cancer Center (Global / Institutional) sponsors 50 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 27 active protocols (19 recruiting now), 13 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)20.0%
Median Closed Enrollment vs National (145 pts)18 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for UNC Lineberger Comprehensive Cancer Center
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)50
Active Pipeline (Recruiting Now)27 (19)
Completed vs Stopped Early13 / 10 (20.0%)
Median Closed Actual Enrollment18 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With UNC Lineberger Comprehensive Cancer Center
Hospital Research SiteLocationShared Protocols
UNC Lineberger Comprehensive Cancer CenterChapel Hill, NC6
University of North Carolina at Chapel HillChapel Hill, NC5
University of North CarolinaChapel Hill, NC3

Explore interactive annual charts and M&A subsidiary rollups in the UNC Lineberger Comprehensive Cancer Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI